A Dose Blocked-randomized, Double-blind, Placebo-controlled, Single Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2016
At a glance
- Drugs LC28 0126 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors LG Life Sciences
- 12 Dec 2016 Interim results assessing tolerability and pharmacokinetics published in the British Journal of Clinical Pharmacology (2016).
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 13 Mar 2014 Status changed from recruiting to completed as rported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History